Latest Breaking News On - Trans med - Page 1 : comparemela.com

Share this article Share this article COPENHAGEN, Denmark, May 25, 2021 /PRNewswire/ IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today the appointment of Muhammad Al-Hajj, PhD as Chief Scientific Officer. He will report to the CEO and be based in the Washington DC metro area, United States, where the company will establish an R&D site. Dr. Muhammad Al-Hajj We are thrilled that Dr. Al-Hajj is joining IO Biotech at such an exciting time in the development of our company, said Mai-Britt Zocca, PhD, Chief Executive Officer, and founder of IO Biotech.  He is a well-respected scientific leader with deep expertise and a proven track record in the field of immuno-oncology with expertise in translational medicine and biomarker discovery.  Dr. Al-Hajj will play a pivotal role in harnessing the power of our T-win technology platform to build on our lead progr

United statesUnited kingdomJuniper pointJennifer williamsMai britt zoccaAmy conradMedimmune astrazenecaCompany contactMichigan cancer centerSanford burnham institute in la jollaTranslational sciences at autolusCook williams communications incTranslational sciencesDrug discoveryTranslational medicineSanford burnham institute